Efficacy and Safety of a Novel Paclitaxel-Nano-Coated Balloon for Femoro-Popliteal Angioplasty: 1-Year Results of EffPac Trial.
CONCLUSIONS: The novel DCB was effective and safe for inhibiting restenosis. Moreover, it demonstrated a better improvement in walking than POBA and showed no mortality concerns due to paclitaxel application after 12 months.
PMID: 31687933 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research